Select a company

Go

Company Stage

  • Private (seed)
  • Private (post-seed)
  • Quoted

Sector

  • Energy and Renewables
  • IT & Communications
  • Chemicals & Materials
  • Biotech
  • Healthcare

University

  • University of Bath
  • University of Bristol
  • University of Cardiff
  • University of Glasgow
  • University of Leeds
  • King's College London
  • Queen Mary, University of London
  • University of Manchester
  • University of Nottingham
  • University of Oxford
  • University of Sheffield
  • University of Southampton
  • University of Surrey
  • Swansea University
  • University of York
  • Other

Stakeholder

  • IP Group
  • IP Venture Fund
  • Top 10 Holdings
    by value
Pharma & Biotech

University: Southampton

Company Stage: Private (post-seed)

Website: http://www.iqur.com

Iqur

iQur (formerly HepCgen) was established to develop novel approaches to the diagnosis and treatment of liver disorders, particularly Hepatitis C and liver fibrosis.

The Company has several objectives:

  • To build a novel service based on the effective diagnosis of Hepatitis C
  • To pursue two drug development strategies for novel therapies to combat Hepatitis C
  • To develop novel, non-invasive methods of diagnosing liver fibrosis

As at 31 Dec 2012

IP Group holding

IP Venture Fund* holding

17.5%

2.8%
 

*IP Group has a 10%
economic interest in IP
Venture Fund

Holdings represent undiluted beneficial equity interest excluding debt

Related news

There is currently no news available.

More portfolio news